Baxter Healthcare recently reported the successful inactivation of H5N1 Avian Influenza (bird flu) in the manufacturing of its plasma-derived products. In a recent study, Baxter demonstrated that its standard viral-inactivation techniques, such as pasteurization, heat and solvent-detergent treatment, effectively removed H5N1 from plasma products used to treat hemophilia patients. Results of the study were presented on March 6th by Thomas R. Kreil, PhD, director of global pathogen safety at Baxter BioScience, at a blood safety conference organized by the Cambridge Healthtech Institute in Baltimore, MD.
"Based on available results from other lipid-enveloped viruses, we anticipated that H5N1 influenza would be inactivated during the processing of our plasma-derived therapeutics," said Dr. Kreil. "However, we at Baxter acknowledge that users of plasma-derived therapies are especially concerned about any emerging virus, and thus decided to conduct these tests to reassure people who use plasma-derived therapies from Baxter,” Kreil added.
Baxter manufactures several plasma-derived products that are approved by the U.S. Food and Drug Administration (FDA). Hemofil M® is a plasma-derived, factor VIII product indicated for the prevention and control of hemorrhagic episodes in patients with hemophilia A. Bebulin VH® and Proplex T® are plasma-derived factor IX products indicated for the prevention and control of hemorrhagic episodes in patients with hemophilia B. FEIBA VH® is a plasma-derived product indicated for control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients with inhibitors.
Source: Baxter news release dated March 6, 2006